Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 316-322

  Saffari, Mojtaba ^a   Dinehkabodi, Orkideh Saydi ^a   Ghaffari, Seyed Hamid ^a   Modarressi, Mohammad H ^a   Mansouri, Fatemeh ^a   Heidari, Mansour ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Annexin II; Caprin I; Cathepsin B; cDNA AFLP; p53

Indexed keywords

CAPRIN 1; CATHEPSIN B; CELL CYCLE ASSOCIATED PROTEIN 1; COMPLEMENTARY DNA; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; LIPOCORTIN 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOVIRUS; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DNA SEQUENCE; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; P53 GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANNEXIN A2; BRAIN NEOPLASMS; CATHEPSIN B; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA PRIMERS; DNA, COMPLEMENTARY; GENES, P53; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ADENOVIRIDAE;

EID: 57349124814     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.020     Document Type: Article

References (42)

1. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
2. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
3. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
4. Kumar S., Walia V., Ray M., and Elble R.C. p53 in breast cancer: mutation and countermeasures. Front. Biosci. 12 (2007) 4168-4178
5. Soussi T., and Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 21 (2003) 192-200
6. Nozaki M., Tada M., Kobayashi H., Zhang C.L., Sawamura Y., Abe H., Ishii N., and Van Meir E.G. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncology 1 (1999) 124-137
7. Royds J.A., and Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 13 (2006) 1017-1026
8. Tada M., Iggo R.D., Waridel F., Nozaki M., Matsumoto R., Sawamura Y., Shinohe Y., Ikeda J., and Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcinog. 18 (1997) 171-176
9. Wang Y., Okan I., Szekely L., Klein G., and Wiman K.G. bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. Cell Growth Differ. 6 (1995) 1071-1075
10. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
11. Jen K.-Y., and Cheung V.G. Identification of novel p53 target genes in ionizing radiation response. Cancer Res. 65 (2005) 7666-7673
12. Harada K., and Ogden G.R. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 36 (2000) 3-7
13. Eisold S., Linnebacher M., Ryschich E., Antolovic D., Hinz U., Klar E., and Schmidt J. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J. Gastroenterol. 10 (2004) 3583-3589
14. Gomez-Manzano C., Fueyo J., Kyritsis A.P., Steck P.A., Roth J.A., McDonnell T.J., Steck K.D., Levin V.A., and Yung W.K. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56 (1996) 694-699
15. Cerrato J.A., Khan T., Koul D., Lang F.F., Conrad C.A., Yung W.K.A., and Liu T.-J. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int. J. Oncol. 24 (2004) 409-417
16. Shono T., Tofilon P.J., Schaefer T.S., Parikh D., Liu T.-J., and Lang F.F. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 62 (2002) 1069-1076
17. Adachi J., Ookawa K., Kohno T., Tomizawa Y., Tsuchida S., and Yokota J. Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression. Cell Death Differ. 5 (1998) 148-155
18. Chen X., Ko L.J., Jayaraman L., and Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10 (1996) 2438-2451
19. Schwartzbaum J.A., Fisher J.L., Aldape K.D., and Wrensch M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2 (2006) 494-503
20. Modarressi M.H., Behnam B., Cheng M., Taylor K.E., Wolfe J., and van der Hoorn F.A. Tsga10 encodes a 65-kilodalton protein that is processed to the 27-kilodalton fibrous sheath protein. Biol. Reprod. 70 (2004) 608-615
21. Grill B., Wilson G.M., Zhang K.-X., Wang B., Doyonnas R., Quadroni M., and Schrader J.W. Activation/division of lymphocytes results in increased levels of cytoplasmic activation/proliferation-associated protein-1: prototype of a new family of proteins. J. Immunol. 172 (2004) 2389-2400
22. Wang B., David M.D., and Schrader J.W. Absence of caprin-1 results in defects in cellular proliferation. J. Immunol. 175 (2005) 4274-4282
23. Solomon S., Xu Y., Wang B., David M.D., Schubert P., Kennedy D., and Schrader J.W. Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs. Mol. Cell. Biol. 27 (2007) 2324-2342
24. Erikson E., and Erikson R.L. Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product. Cell 21 (1980) 829-836
25. Gerke V., and Moss S.E. Annexins: from structure to function. Physiol. Rev. 82 (2002) 331-371
26. Jacovina A.T., Zhong F., Khazanova E., Lev E., Deora A.B., and Hajjar K.A. Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J. Biol. Chem. 276 (2001) 49350-49358
27. Gillette J.M., Chan D.C., and Nielsen-Preiss S.M. Annexin 2 expression is reduced in human osteosarcoma metastases. J. Cell. Biochem. 92 (2004) 820-832
28. Chetcuti A., Margan S.H., Russell P., Mann S., Millar D.S., Clark S.J., Rogers J., Handelsman D.J., and Dong Q. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 61 (2001) 6331-6334
29. Liu J.-W., Shen J.-J., Tanzillo-Swarts A., Bhatia B., Maldonado C.M., Person M.D., Lau S.S., and Tang D.G. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22 (2003) 1475-1485
30. Mackay E.A., Ehrhard A., Moniatte M., Guenet C., Tardif C., Tarnus C., Sorokine O., Heintzelmann B., Nay C., Remy J.M., Higaki J., Van Dorsselaer A., Wagner J., Danzin C., and Mamont P. A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 244 (1997) 414-425
31. Kruszewski W.J., Rzepko R., Wojtacki J., Skokowski J., Kopacz A., Jaskiewicz K., and Drucis K. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 51 (2004) 38-43
32. Yanamandra N., Gumidyala K.V., Waldron K.G., Gujrati M., Olivero W.C., Dinh D.H., Rao J.S., and Mohanam S. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23 (2004) 2224-2230
33. Lakka S.S., Gondi C.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., and Rao J.S. Inhibition of cathepsin B MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23 (2004) 4681-4689
34. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R., and Rao J.S. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor antisense cathepsin B inhibits tumor growth invasion and angiogenesis in gliomas. Cancer Res. 64 (2004) 4069-4077
35. Mai J., Sameni M., Mikkelsen T., and Sloane B.F. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 383 (2002) 1407-1413
36. Hook V.Y.H. Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease. Biol. Chem. 387 (2006) 1429-1439
37. Qian F., Bajkowski A.S., Steiner D.F., Chan S.J., and Frankfater A. Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res. 49 (1989) 4870-4875
38. Buck M.R., Karustis D.G., Day N.A., Honn K.V., and Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282 Pt. 1 (1992) 273-278
39. Sevenich L., Pennacchio L.A., Peters C., and Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biol. Chem. 387 (2006) 885-891
40. Huang Q., Raya A., DeJesus P., Chao S.-H., Quon K.C., Caldwell J.S., Chanda S.K., Izpisua-Belmonte J.C., and Schultz P.G. Identification of p53 regulators by genome-wide functional analysis. Proc. Natl. Acad. Sci. USA 101 (2004) 3456-3461
41. Liang H., and Lunec J. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene 361 (2005) 112-118
42. Reczek E.E., Flores E.R., Tsay A.S., Attardi L.D., and Jacks T. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol. Cancer Res. 1 (2003) 1048-1057